MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known 10/572,740 INFORMATION DISCLOSURE Application Number STATEMENT BY APPLICANT Filing Date 10/15/2004 First Named Inventor Robert HOFMEISTE Date Submitted: July 11, 2006 Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned 028622-0148 Attorney Docket Number 1 Sheet

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		No. of Data day of Australa 6	Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
/AMG/	A1	4,361,549		Kung et al.	11-30-1982	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
		Serial Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Fo Office ³	oreign Patent D	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
/AMG/	A2	WO	92/10755	A1	Novo Nordisk	06-25-1992		
/AMG/	A3	wo	00/34317	A2	Biovation Limited	06-15-2000		
/AMG/	A4	wo	98/52976	A1	Biovation Limited	11-26-1998		
/AMG/	A5	wo	02/079415	A2	Lexigen Pharmaceuticals Corp.	10-10-2002		
/AMG/	A6	WO	02/012899	A2	Biovation Limited	02-14-2002		
/AMG/	A7	WO	02/069232	A2	Merck Patent GmbH	09-06-2002		-
	i	1						

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				

Evaminor		Date	04/00/0040
Examiner Signature	/Anne M. Gussow/	Considered	01/22/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language